stockrowInsulet Corporation
PODD Healthcare Medical Devices
Insulet Corporation’s revenue for fiscal 2025 (year ended December 2025) was $2.7 billion, up 30.7% from fiscal 2024.
- Revenue
- +19.2%
- EPS
- +64.1%
- Free cash flow
- −29.8%
- Total debt
- −5.19%
Quarter to September 2026, against a year earlier
Follow PODD
Alert me
Insulet Corporation (PODD) Revenue growth
Insulet Corporation's revenue growth over the twelve months to 30 September 2026 was 26.5%, down 4.3 percentage points from fiscal 2025 (30.7%). Over the past ten years it has ranged from 14.1% (fiscal 2015) to 39.1% (fiscal 2016); the current reading is higher than 82% of that period. That is above the Medical Devices industry median of 10.4% and above the Healthcare sector median of 7.80%.
Revenue growth, annual
Embed this chart
Annual newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| FY2025 | 30.7% | 8.66 |
| FY2024 | 22.1% | (7.95) |
| FY2023 | 30.0% | 11.23 |
| FY2022 | 18.8% | (2.70) |
| FY2021 | 21.5% | (1.02) |
| FY2020 | 22.5% | (8.42) |
| FY2019 | 30.9% | 9.37 |
| FY2018 | 21.6% | (4.82) |
| FY2017 | 26.4% | (12.69) |
| FY2016 | 39.1% | 24.99 |
Quarterly newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| Sep 2026 | 19.2% | (4.30) |
| Jun 2026 | 23.5% | (10.36) |
| Mar 2026 | 33.9% | 2.71 |
| Dec 2025 | 31.2% | 1.30 |
| 43 more quarters | Free account |
Against its own ten years
Revenue growth against peers
| Company | Revenue growth |
|---|---|
| GKOS Glaukos Corporation compare | 46.9% |
| PODD Insulet Corporation | 26.5% |
| PEN Penumbra, Inc. compare | 17.0% |
| GMED Globus Medical, Inc. compare | 13.4% |
| SNN Smith & Nephew SNATS, Inc. compare | 4.81% |
| BRKR Bruker Corporation compare | 2.16% |
| BIO.B Bio-Rad Laboratories, Inc. compare | 1.38% |
| BIO Bio-Rad Laboratories, Inc. compare | 1.38% |
| TXG 10x Genomics compare | −4.28% |
| Medical Devices industry median | 10.4% |
| Healthcare sector median | 7.80% |
| Market median | 7.58% |
What Revenue growth is
Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.
(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|
More on PODD
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement